Research from the laboratory to the patient and vice versa
Around 20 innovative research projects are initiated at the Center for Cancer Research every year. Due to the affiliation of the center to the Medical University of Vienna and the proximity to the AKH Wien (Vienna General Hospital), basic research and clinic can work together very closely and the research results flow directly into diagnosis and therapy.
Our vision: Cancer is a conquerable and curable disease!
Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo
Schelch K, Emminger D, Zitta B, Johnson TG, Kopatz V, Eder S, Ries A, Stefanelli A, Heffeter P, Hoda MA, Hoetzenecker K, Dome B, Berger W, Reid G, Grusch M.
read more
Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells
Kornélia Szebényi, András Füredi, Eszter Bajtai, Sai Nagender Sama, Agnes Csiszar, Balázs Gombos, Pál Szabó, Michael Grusch, Gergely Szakács
read more
Degradable Bottlebrush Polypeptides and the Impact of their Architecture on Cell Uptake, Pharmacokinetics, and Biodistribution In Vivo
Paul Strasser, Bianca Montsch, Silvia Weiss, Haider Sami, Christoph Kugler, Sonja Hager, Hemma Schueffl, Robert Mader, Oliver Brüggemann, Christian R Kowol, Manfred Ogris , Petra Heffeter, Ian Teasdale
read more
Mesothelioma‑associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c‑Met/PI3K and WNT signaling but do not protect against cisplatin
Alexander Ries, Daniela Flehberger, Astrid Slany, Christine Pirker, Johanna C. Mader, Thomas Mohr, Karin Schelch, Katharina Sinn, Berta Mosleh, Mir Alireza Hoda, Balazs Dome, Helmut Dolznig, Georg Krupitza, Leonhard Müllauer, Christopher Gerner, Walter Berger & Michael Grusch
read more
Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound
Ertl IE, Lemberger U, Ilijazi D, Hassler MR, Bruchbacher A, Brettner R, Kronabitter H, Gutmann M, Vician P, Zeitler G, Koren A, Lardeau CH, Mohr T, Haitel A, Compérat E, Oszwald A, Wasinger G, Clozel T, Elemento O, Kubicek S, Berger W, Shariat SF.
read more
In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer
Beáta Szeitz, Zsolt Megyesfalvi, Nicole Woldmar, Zsuzsanna Valkó, Anna Schwendenwein, Nándor Bárány, Sándor Paku, Viktória László, Helga Kiss, Edina Bugyik, Christian Lang, Attila Marcell Szász, Luciana Pizzatti, Krisztina Bogos, Mir Alireza Hoda, Konrad Hoetzenecker, György Marko-Varga, Peter Horvatovich, Balázs Döme, Karin Schelch, Melinda Rezeli
read more
The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation
Baier D, Schoenhacker-Alte B, Rusz M, Pirker C, Mohr T, Mendrina T, Kirchhofer D, Meier-Menches SM, Hohenwallner K, Schaier M, Rampler E, Koellensperger G, Heffeter P, Keppler B, Berger W.
read more
The AP-1 transcription factors c-Jun and JunB are essential for CD8α conventional dendritic cell identity
Novoszel P, Drobits B, Holcmann M, Fernandes CS, Tschismarov R, Derdak S, Decker T, Wagner EF, Sibilia M.
read more